Labcorp shares gain more than 3% after unveiling consumer-focused genetic testing service

Traders Union
All News
Stocks
Labcorp surges 3.22% today to $310.88

Highlights

Labcorp launched a consumer genetic testing panel analyzing 163 genes related to over 100 health conditions, expanding its direct-to-consumer portfolio.
The Marker by Labcorp test is available nationwide with online results and access to licensed genetic counselors for patients.
Labcorp shares surged to $310.88 amid strong bullish momentum, with price expected to fluctuate between $298.79 and $324.15 in the near term.

Consumer test rollout and wide access drive investor optimism

Labcorp announced the launch of the Marker by Labcorp Genetic Health Panel, a consumer-focused genetic testing service analyzing 163 genes tied to over 100 health conditions. The test can be purchased directly through Labcorp OnDemand with blood draws available nationwide at over 2,200 Labcorp service centers. Results are delivered securely online with access to licensed genetic counselors for additional support.

Anton Kharitonov, expert at Traders Union, highlights that Labcorp’s technicals look stretched following the recent uptick. He notes that the overbought signals from RSI and Stochastic RSI raise red flags, with momentum possibly peaking. Kharitonov remains cautious about the sustainability of gains, emphasizing that strong buying on news often precedes corrective periods. He observes the broad bullish trend but stresses risks if $305.16 support fails. "I see the current surge as overextended — prudent investors should watch for retracement signs before chasing further upside," says Kharitonov.

Viktoras Karapetjanc, expert at Traders Union, believes the launch of Marker by Labcorp signals further institutional interest and long-term growth potential. He sees the company’s robust fundamentals, consumer-focused innovation, and strong technical alignment as reinforcing the bullish outlook. Karapetjanc points to broad market support and sustained demand flows following recent news. "Bullish structure remains intact and further growth is expected as the market offers multiple setups for upside breakout," he states.

Sholanke Dele, market strategist, sees Labcorp's jump as driven by optimistic sentiment around the new genetic panel. He cautions that the overbought readings suggest a short-term pullback is likely if broader markets turn risk-off. Dele argues that upside looks limited at present levels without fresh catalysts. "With the stock so extended, I would stay defensive until momentum resets and a clearer macro backdrop emerges," Dele advises.

Technical breakout as overbought signals challenge strong uptrend

Labcorp is trading above its 20-day ($282.59), 50-day ($269.44), and 200-day ($267.58) moving averages, reflecting strong bullish alignment across short-, medium-, and long-term trends. The nearest resistance is at $313.85, with the closest support at $305.16. The longer-term trend remains bullish, as indicated by the MA-50 vs MA-200 alignment and confirmation from the Ichimoku Kijun at $277.37. Momentum signals are robust, with a MACD of 8.57 indicating a buy, and the ADX at 18.58 showing neutral trend strength. However, overbought conditions are flagged by the RSI at 73.72, Stochastic RSI at 100, CCI at 213.77, and BBP at 16.27. Intraday price action is strong, supported by the Awesome Oscillator, with a 2.85% intraday volatility and the stock sitting mid-range for the session. Upward momentum is pronounced, but several indicators point to the move being extended into overbought territory.

Previously it was reported that Labcorp agreed to pay $14.5 million to resolve allegations of improper Medicare billing related to unnecessary urine drug testing. The successful launch of the Marker by Labcorp Genetic Health Panel, alongside strong technical momentum, introduces new growth potential, and traders should monitor for a breakout above $313.85 as confirmation of continued upward strength.

Source of Data: LH Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.